Pharma BD Deal Intelligence
Not actually an acquisition — a 2014 BMS/Five Prime checkpoint discovery collaboration whose flagship follow-on asset (cabiralizumab) failed Phase 2 in 2020 and was shelved; BMS never owned Five Prime, which was later bought by Amgen for an unrelated drug.
Full analysis, sources & comparables →Trade coverage reports the exclusive clinical collaboration to evaluate the combination of investigational immunotherapies Opdivo and FPA008 in six tumor…
GEN reported BMS expanded the original 2014 clinical collaboration into a $1.74B license ($350M upfront, $1.05B oncology milestones per product), framing it as…
MedCity News reported Five Prime shares fell 10% on the failure announcement, and BMS stated it had 'no near-term plans for additional sponsored development of…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
BMS and Five Prime entered an exclusive Phase 1a/1b clinical-collaboration agreement to evaluate cabiralizumab (FPA008, anti-CSF-1R) combined with Opdivo across six tumor types. Strategically notable as foundation for Five Prime's eventual $1.9B 2015 expanded oncology pact and Amgen's acquisition of Five Prime in 2021.
Not actually an acquisition — a 2014 BMS/Five Prime checkpoint discovery collaboration whose flagship follow-on asset (cabiralizumab) failed Phase 2 in 2020 and was shelved; BMS never owned Five Prime, which was later bought by Amgen for an unrelated drug.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Five Prime Therapeutics (this deal) | 2014 | — | 23 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2014 deals · Bristol-Myers Squibb Company deals · Oncology deals